Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MolliProct
- Development stage
- Unknown
- Lead developer
- ESPA Biomedical
- Administration
- Oral
01
Overview
MolliProct is an oral plant-extract and mineral dietary supplement developed by ESPA Biomedical and distributed by CTS in Israel. Formulated as a synergistic combination of four plant extracts and magnesium oxide, it is designed to regulate bowel movements and alleviate constipation or bowel irregularity. It is marketed as an over-the-counter (OTC) consumer health product in the form of capsules.
- Brand names
- MolliProct
- Other names
- מוליפרוקט
Beyond the preview
Go deeper on MolliProct.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MolliProct.